Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (362)	5/22/1998 11:25:00 AM
From: Renee	Read Replies (1) \| Respond to of 1025

Just visited the BM website at boehringer-mannheim.com It looks like the test menu will be 35 shortly. 11 tests are listed but don't have check marks. I interpret that to mean they will soon be available for sale perhaps after approval. Pacific Growth, 1st Boston and NationsBank all issued research reports after the conference call reiterating their buy ratings. 1st Boston 12 month target is 50, Pacific 75-90 and Nations 70. All three firms predict quarterly losses to continue in FY 99. Pacific estimates $4.96 after tax in FY 2003. A recurring theme of the writeups is that at current prices you are getting the non Roche\BM business for free while it should fetch around 30 or so on its own. Hopefully the POC deal will materialize soon and send the shares back into the 40's.